- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.30 Å
- Oligo State
- hetero-1-1-1-mer
- Ligands
- 2 x NAG- NAG- FUC: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x NAG- FUC: alpha-L-fucopyranose-(1-6)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x MAN: alpha-D-mannopyranose(Post Translational Modification)
- 4 x SO4: SULFATE ION(Non-functional Binders)
- 1 x CYS: CYSTEINE(Non-covalent)
- 2 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Klein, C. et al., Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology (2017)
- Release Date
- 2017-05-03
- Peptides
- Interleukin-2 receptor subunit beta: A
Cytokine receptor common subunit gamma: B
Interleukin-2: C - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
BB
CC
D